Coordinated Financial Services Inc. Purchases New Shares in Stryker Co. (NYSE:SYK)

Coordinated Financial Services Inc. acquired a new position in shares of Stryker Co. (NYSE:SYK) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,748 shares of the medical technology company’s stock, valued at approximately $629,000.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker during the fourth quarter worth about $25,000. Dunhill Financial LLC lifted its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the period. Centricity Wealth Management LLC bought a new stake in Stryker during the fourth quarter worth about $30,000. BankPlus Trust Department bought a new stake in Stryker during the fourth quarter worth about $33,000. Finally, Darwin Wealth Management LLC bought a new stake in Stryker during the third quarter worth about $36,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $379.28 on Friday. The company has a market cap of $144.73 billion, a price-to-earnings ratio of 48.88, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average of $382.45 and a 200-day moving average of $372.99.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 earnings per share. On average, equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Argus set a $450.00 target price on shares of Stryker in a report on Monday, February 3rd. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.